There are several variables that come into play when considering the relapse or success rates of Victrelis therapy. To determine an actual rate would require several considerations. Things like prior treatment, length of disease, fibrosis, etc., etc. The list is long. I was concerned about the decision to end treatment at week 28, because my Hepa failed to perform a required Viral Load early in treatment which is normally used to determine Tx length were my VL still detectable. But after the 12th week VL showed I was UND, the decision was made to end Tx at 28 weeks. I experienced some real problems from anemia, but anemia itself was a sign of effectiveness with the earlier protocols. The people treating with the newest DAA's have been spared some real misery in that respect.
Tig
libgirl07 said
Jul 11, 2014
I'm curious as to how many people relapsed on triple therapy with Vic. What's your genotype have you treated before how many weeks were you treated?
Hi Nicole,
There are several variables that come into play when considering the relapse or success rates of Victrelis therapy. To determine an actual rate would require several considerations. Things like prior treatment, length of disease, fibrosis, etc., etc. The list is long. I was concerned about the decision to end treatment at week 28, because my Hepa failed to perform a required Viral Load early in treatment which is normally used to determine Tx length were my VL still detectable. But after the 12th week VL showed I was UND, the decision was made to end Tx at 28 weeks. I experienced some real problems from anemia, but anemia itself was a sign of effectiveness with the earlier protocols. The people treating with the newest DAA's have been spared some real misery in that respect.
Tig
I'm curious as to how many people relapsed on triple therapy with Vic. What's your genotype have you treated before how many weeks were you treated?